Immucell Corp (ICCC) — 分析摘要
Immucell Corp(ICCC)的市值为100.24百万美元,最近一年的营收同比增长了+4.3%。净利润率为-3.8%。当前市盈率为-183.8倍。
核心要点
- 营收同比变化+4.3%
- 净利润率-3.8%
- 市盈率-183.8倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比,ICCC的营收增长为+4.3%,市盈率为-183.8倍。
Immucell Corp (ICCC)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报,没有触发重大的信用、利润率或趋势红旗。
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
73
总部
PORTLAND, ME
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。